Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Usana Health Sciences (USNA) Common Equity (2016 - 2026)

Usana Health Sciences (USNA) has disclosed Common Equity for 17 consecutive years, with $533.1 million as the latest value for Q1 2026.

  • Quarterly Common Equity changed 0.19% to $533.1 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $533.1 million through Jan 2026, changed 0.19% year-over-year, with the annual reading at $533.1 million for FY2026, 0.19% changed from the prior year.
  • Common Equity for Q1 2026 was $533.1 million at Usana Health Sciences, up from $528.1 million in the prior quarter.
  • The five-year high for Common Equity was $533.1 million in Q1 2026, with the low at $389.9 million in Q2 2022.
  • Average Common Equity over 5 years is $478.0 million, with a median of $497.2 million recorded in 2023.
  • The sharpest move saw Common Equity fell 10.53% in 2022, then rose 16.77% in 2023.
  • Over 5 years, Common Equity stood at $434.5 million in 2022, then rose by 14.44% to $497.2 million in 2023, then grew by 7.02% to $532.1 million in 2024, then fell by 0.76% to $528.1 million in 2025, then increased by 0.95% to $533.1 million in 2026.
  • According to Business Quant data, Common Equity over the past three periods came in at $533.1 million, $528.1 million, and $531.1 million for Q1 2026, Q3 2025, and Q2 2025 respectively.